Does atrial fibrillation confer a hypercoagulable state?
about
Clinical review: clinical management of atrial fibrillation - rate control versus rhythm controlEffects of congestive heart failure on plasma von Willebrand factor and soluble P-selectin concentrations in patients with non-valvar atrial fibrillationOptimising stroke prevention in non-valvular atrial fibrillationManagement of atrial fibrillationEHRA/HRS/APHRS/SOLAECE expert consensus on Atrial cardiomyopathies: Definition, characterisation, and clinical implication.Recent developments in atrial fibrillation.Oral anticoagulation is frequently discontinued after ablation of paroxysmal atrial fibrillation despite previous stroke: data from the German Ablation Registry.Atrial high-rate episodes and stroke prevention.When atrial fibrillation occurs with pulmonary embolism, is it the chicken or the egg?Update on Atrial Fibrillation: Restoration of Sinus Rhythm or Ventricular Rate Control?Intracardiac Hemostasis and Fibrinolysis Parameters in Patients with Atrial Fibrillation.Atrial fibrillation and stroke: what we know, what's new, and what we should do now.The expression levels of plasma micoRNAs in atrial fibrillation patients.Effects of radiofrequency catheter ablation of atrial fibrillation on soluble P-selectin, von Willebrand factor and IL-6 in the peripheral and cardiac circulationAtrial fibrillation: epidemiologic considerations and rationale for conversion and maintenance of sinus rhythm.The effects of magnesium on the course of atrial fibrillation and coagulation in patients with atrial fibrillation undergoing mitral valve annuloplastyPlatelet activation, haemorheology and thrombogenesis in acute atrial fibrillation: a comparison with permanent atrial fibrillation.Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillationAssociation of hemostatic markers with atrial fibrillation: a meta-analysis and meta-regression.The renin-angiotensin-aldosterone system in atrial fibrillation: a new therapeutic target?Antithrombotic treatment in atrial fibrillation.Acute anticoagulation adjustment in patients with atrial fibrillation at risk for stroke: approaches, strategies, risks and benefits.ABC of atrial fibrillation. Antithrombotic treatment for atrial fibrillation.Fluctuations in coagulation activity among patients with atrial fibrillation who are stably anticoagulated.Stroke prevention in atrial fibrillation patients.Update on the management of atrial fibrillation: anticoagulation and medical therapy.A review of oral anticoagulants in patients with atrial fibrillation.Catheter ablation of atrial fibrillation in the elderly: does the benefit outweigh the risk?Hypercoagulability, D-dimer and atrial fibrillation: an overview of biological and clinical evidence.Hypercoagulability and haemodynamic abnormalities in atrial fibrillation.Factor VII -323 decanucleotide D/I polymorphism in atrial fibrillation: implications for the prothrombotic state and stroke risk.Is atrial fibrillation associated with pulmonary embolism?The effects of eosinophil on the left atrial thrombus in patients with atrial fibrillation.A longitudinal population-based study of prothrombotic factors in elderly subjects with atrial fibrillation: the Rotterdam Study 1990-1999.Effect of sinus rhythm restoration on markers of thrombin generation in atrial fibrillation.Non-rheumatic atrial fibrillation and stroke.Atrial fibrillation and percutaneous coronary intervention: stroke, thrombosis, and bleeding.EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication.
P2860
Q24800344-256A0663-4A46-4CBB-AFD6-0DEFAB898D6AQ28175492-999EEC83-5979-4A10-8D28-6EED0DE6CAD6Q28200609-31602FD8-DD6E-4B89-9A14-ED8AC60D52F6Q28217428-0DBA3F32-3AC8-4747-9177-07AB7F844C68Q30375302-453DFED6-D7F9-4021-B7C8-E81CE4276D0AQ30854979-C7162EEE-73D4-4EB0-8826-205D6CAAC728Q30881747-1BC25D78-4214-4FC7-A4E2-B74C42997F3FQ33589724-BDE74B90-278F-48C8-8AAB-654A9507DECDQ33611230-3DE5A55D-9684-4056-B835-9AC5D978024FQ33843408-31BD238D-5FA4-4691-BD8D-DCE782D770C4Q33872912-3178A709-F265-4626-84B0-6ABF84079677Q34025564-C10E8748-5D48-4386-85B4-0E620D9F517FQ34427635-888C5930-B5F1-47C8-B182-54A0246288B4Q34497358-99D5442F-0565-493C-84C1-7114A6DE548AQ35127391-002D1304-09A6-401F-8FA2-57BD6E685B0BQ35406672-961D25FD-7547-4F4B-946D-827CC8F13C6BQ35581473-735766F0-1C35-4372-9615-741F7AD7B881Q35582996-F307179E-804B-49CF-8D7C-7DADF279CC1EQ35605552-4E9082A1-EC3B-4266-AC8F-6A9DE76BA79FQ35671248-6654562A-B3D2-4D1F-9C75-123D85297442Q35771277-222CBDB9-499D-486A-9588-9DA5AD06AE98Q36216795-F83B2CC7-A39A-4372-8E54-2236E3D156CDQ36596173-38FA6186-9109-41E9-A890-36AD1E9333FBQ37608475-EC2F6E50-25CC-45AD-A517-F13AEA367C43Q37780750-8A6BA692-BE56-432B-93A6-F7AF22DFF1BFQ37899797-007653CE-F044-4A34-A3CA-CB59F4690FD2Q38074330-63181444-0D6A-4B6E-9778-A041D7BCB890Q38113245-6A5CE1BC-BE8D-447E-B40F-01FA43512112Q38215163-8C6FC89B-78C2-44AB-9A2A-87BE9BE4652DQ41343151-C16579E4-7CE5-4E28-AE65-622F70DC0EDAQ43547874-EDD017C9-0B6D-4B72-B2B6-34B8A82AB7A9Q43942718-4D58C15C-AB69-425F-AB4B-4D0A23A7EC07Q44314035-6EC7C265-DE92-4331-BA37-04E42152DF7EQ45060767-250BE8F4-85EC-43E8-BE9B-DE4D4A782EC7Q47106384-A446F6BA-E7AA-466B-809D-298C869D7A91Q50661544-8720A3E4-6D56-411D-BCF9-9B73C07822E5Q53158514-D120C8FD-42E6-4ECF-8266-9836470373C8Q55638585-5AD94C07-F692-42BE-B9EC-8DA4035D304C
P2860
Does atrial fibrillation confer a hypercoagulable state?
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Does atrial fibrillation confer a hypercoagulable state?
@en
type
label
Does atrial fibrillation confer a hypercoagulable state?
@en
prefLabel
Does atrial fibrillation confer a hypercoagulable state?
@en
P1433
P1476
Does atrial fibrillation confer a hypercoagulable state?
@en
P2093
P304
P356
10.1016/S0140-6736(95)92339-X
P407
P577
1995-11-01T00:00:00Z